More than a century has passed since pathological protein aggregates were first identified as defining hallmarks for several neurodegenerative diseases (NDDs), including Alzheimer’s and Parkinson’s diseases. Yet, we still do not have effective therapies to treat or impede the progression of these debilitating diseases or the diagnostics tools for early detection and monitoring.

This webinar will explore some of the underlying reasons for the drug development failures in NDDs, including the failure to embrace the neuropathological complexity and clinical heterogeneity of NDDs. Using recent findings and Parkinson’s disease as a case study, this webinar will demonstrate how new advances in chemical biology, imaging, protein structure amplification, and omics technologies have enabled us to deconstruct and reconstruct the complexity of brain pathologies and disease mechanisms in NDDs. The discussions will make the case that effective treatments of Parkinson’s disease and other NDDs will require personalized combination therapies that account for their clinical heterogeneity and the complexity of the molecular mechanisms driving neurodegeneration and disease progression. 

Speaker:

Register now